MEDP earnings — 2026-07-22

Medpace's Q2 2026 print read as a beat: American Banking News (2026-07-28) reports the stock reaching a new 52-week high on "better-than-expected earnings," and MarketBeat (2026-07-28) logged price-target hikes to $609 (Truist, up from $462, Hold maintained) and $624 (Baird, Neutral maintained) in the print's wake. The desk's own July 25 market brief credits Medpace with raising its 2026 guide and shares jumping +11.8%, citing Yahoo Finance's July 24 coverage — a figure the biotech-capital-cycle perspective log's 2026-07-28 entry flags as still unverified against a primary filing or transcript, since no EPS or revenue dollar figures appear on any source on disk. Full-scan summaries dated 2026-07-28 (biotech-capital-cycle) show MEDP at $570.97, RSI 61.3, +7.4% over 7 days and +6.8% over 30 days, still up on the print despite a -3.1% pullback on the latest session. For the biotech-capital-cycle thesis, this is domino #3 (CRO book-to-bill) moving from "pending confirmation" to "reported bullish, unverified" — supportive, but not yet a fired ratification of the funding-cycle turn.